Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02224599 · ClinicalTrials.gov registry record · Phase 1
Cyclophosphamide, TAPA-Pulsed Dendritic Cell Therapy and Imiquimod in Progressive and/or Refractory Solid Malignancies
A Phase 1 study, sponsored by Kiromic BioPharma.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT02224599 is a Phase 1 study that was terminated before completion, run by Kiromic BioPharma. The registered enrollment target is 3 participants.
The verdict
NCT02224599, a Phase 1 study, was terminated before completion, sponsored by Kiromic BioPharma.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
Patients diagnosed with progressive and/or refractory solid malignancies, who have failed conventional therapy, and have no available, potentially curative therapeutic options, will be candidates for this Phase I/II study. Following confirmation of disease progression and/or refractoriness, eligible patients who agree to participate and sign an informed consent form will have their tumor cells/tissues and/or blood analyzed for the expression of a specific panel of Tumor Associated Peptide Antigens (TAPAs), including Sp17, ropporin, AKAP-4, PTTG1, Span-xb, Her-2/neu, HM1.24, NY-ESO-1 and MAGE-1.
Interventions
- DRUG Cyclophosphamide Pill
- BIOLOGICAL TAPA-pulsed DC vaccine
- DRUG Imiquimod Topical Cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2017-07-28 |
| Est. Completion | 2018-08-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02224599
The ClinicalTrials.gov registry entry for NCT02224599 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kiromic BioPharma, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cyclophosphamide Pill is the first listed.
NCT02224599 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02224599 about?
NCT02224599 is a clinical study titled "Cyclophosphamide, TAPA-Pulsed Dendritic Cell Therapy and Imiquimod in Progressive and/or Refractory Solid Malignancies". Patients diagnosed with progressive and/or refractory solid malignancies, who have failed conventional therapy, and have no available, potentially curative therapeutic options, will be candidates for this Phase I/II study. Following confirmation of disease progression and/or refractoriness, eligible...
What is the current status of trial NCT02224599?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2017-07-28. Estimated completion is 2018-08-30.
What interventions are being tested in trial NCT02224599?
The interventions under investigation include: Cyclophosphamide Pill (DRUG), TAPA-pulsed DC vaccine (BIOLOGICAL), Imiquimod Topical Cream (DRUG).
Who is sponsoring clinical trial NCT02224599?
This trial is sponsored by Kiromic BioPharma, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.